From regular exercise to eating well, there are many things you can do to protect your joints. Try these tips for healthy ...

Among a large cohort of young adults with psoriatic arthritis, 38.8% exhibited radiographic evidence of degenerative disc disease. Researchers in Canada conducted a retrospective cohort study to ...

IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including active psoriatic arthritis. In the phase 3b APEX ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

Patients with psoriatic arthritis (PsA) experienced longer diagnostic delays than matched patients with rheumatoid arthritis (RA). Patients with polyarticular PsA received less intensive disease ...

Psoriatic arthritis represents a complex intersection ... regimens focusing on joint protection principles, strengthening exercises, and range-of-motion preservation. Occupational therapy ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. Findings from the Phase ...

Medically reviewed by Anita C. Chandrasekaran, MD Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that combines the skin-related symptoms of psoriasis with the joint-related symptoms ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...